清宣止咳颗粒与小儿宝泰康颗粒治疗儿童感冒风热证经济学对比

Economic Comparison of Qingxuan Zhike Granules Versus Xiao′er Baotaikang Granules in the Treatment of Children with Cold of Wind-Heat Syndrome

目的 为临床优选小儿感冒风热证的治疗方案提供依据。方法 基于一项随机对照试验数据对清宣止咳颗粒组(试验组)和小儿宝泰康颗粒组(对照组)方案进行经济学评价,分别以证候痊愈率、解热时间和证候总积分为效果指标,结合文献和官方数据计算直接医疗成本。采用成本-效果分析法计算增量成本-效果比(ICER);采用单因素敏感性分析法分析对ICER影响较大的因素。结果 两组的解热时间、证候总积分均无显著差异(P> 0.05);人均治疗成本(176.79元比256.94元)方面,试验组更具有经济学优势。两组的ICER为-4.29,即与对照组比较,试验组具有绝对优势。单因素敏感性分析结果表明,对ICER影响较大的主要因素为小儿保泰康颗粒的药品费用。结论 清宣止咳颗粒治疗小儿感冒风热证具有较好的成本-效果比。

Objective To provide evidence for the clinical optimal plan of the treatment of children with cold of wind-heat syndrome.Methods Based on the data of a randomized controlled trial,the economic evaluation was conducted on the plan of Qingxuan Zhike Granules group(the test group)and the plan of Xiao′er Baotaikang Granules group(the control group). Based on the literature and official data,the direct medical cost was calculated by taking the syndrome recovery rate,antipyretic time and total score of symptoms as the efficacy indicators. The incremental cost-effectiveness ratio(ICER) was calculated by cost-effectiveness analysis. The factors that have a greater impact on ICER were analyzed by the one-way sensitivity analysis.Results There was no significant difference in antipyretic time and total score of syndromes between the two groups(P > 0. 05). The per capita treatment cost in the test group had more economic advantages than that in the control group(CNY 176. 79 vs. CNY 256. 94). The ICER in the two groups was-4. 29,which indicated that the ICER in the test group had absolute advantages compared with that in the control group. The results of the one-way sensitivity analysis showed that the major factor influencing ICER was the drug cost of Xiao′er Baotaikang Granules.Conclusion Qingxuan Zhike Granules have a better cost-effectiveness ratio in the treatment of children with cold of wind-heat syndrome.